38 results about "Mycobacterium tuberculosis H37Rv" patented technology

The invention relates to a coding gene of Mycobacterium tuberculosis H37Rv. The coding gene can be used as a standard gene for molecular identification of a Mycobacterium tuberculosis complex group and can be used for molecular identification and clinical detection of the Mycobacterium tuberculosis complex group.

The invention relates to a specific electrochemical immunosensor for tuberculosis serodiagnosis, and belongs to the field of important epidemic prevention and cure. The immunosensor is a novel biosensor which is constructed through combining an immunoassay and a high sensitive sensing technology, and is applicable for analyzing and studying trace quantity of immunogenicity substance. According to the present invention, based on preparatory antigen marking and screening work, mycobacterium tuberculosis Rv2175c gene encoding protein (hereinafter referred to as specific antigen) is adopted as a specific antigen, a high sensitive electrochemical immunosensor is constructed, an antibody recognized by the specific antigen is detected in serum to realize the tuberculosis serodiagnosis. A method for the tuberculosis serodiagnosis comprises the following steps: (1) cloning the Rv2175c gene of the mycobacterium tuberculosis H37Rv; (2) heterologous expressing the purified specific antigen in escherichia coli; (3) preparing antibody serum on rabbits by using the specific antigen to be adopted as a positive control; (4) preparing the electrochemical immunosensor; (5) detecting the serum of healthy people and the serum of tuberculosis patients. With the present invention, the healthy people and the tuberculosis patients can be distinguished well through difference of current changing detected by the immunosensor, such that a purpose of serodiagnosis is achieved.

The invention discloses a high throughput screening method of a mycobacterium tuberculosis alpha-D-glucose-1-thymine phosphate transferase inhibitor. A method for rapidly and accurately measuring the activity of the mycobacterium tuberculosis alpha-D-glucose-1-thymine phosphate transferase is established by the following steps of: cloning an rmlA gene from a mycobacterium tuberculosis H37Rv strain genome by using the molecular cloning technology; simultaneously creating an Escherichia coli engineering strain which highly expresses alpha-D-glucose-1-thymine phosphate transferase; and purifying the engineering strain to obtain mycobacterium tuberculosis alpha-D-glucose-1-thymine phosphate transferase by using affinity chromatography.. The transferase activity measuring method screens a molecular model of the mycobacterium tuberculosis alpha-D-glucose-1-thymine phosphate transferase inhibitor and is used for the high throughout screening of the mycobacterium tuberculosis alpha-D-glucose-1-thymine phosphate transferase inhibitor in combinational compound libraries, traditional Chinese medicine and natural products.

The invention relates to a tuberculosis polypeptide vaccine for preventing and treating tuberculosis and its preparation method and application, belonging to the technical field of biopharmaceutical engineering. The tuberculosis polypeptide vaccine in the present invention includes a tuberculosis polypeptide and a carrier, and the tuberculosis polypeptide includes the 81-100 amino acid fragment of the Rv0180c protein of Mycobacterium tuberculosis, the 261-280 amino acid fragment of the Rv0227c protein, and the 281-300 amino acid fragment of the Rv2004c protein. one or more. The polypeptide fragments selected in the present invention are the key polypeptide fragments in the important protective antigens of MTB, and the main protective epitopes of multiple antigens are concentrated, which can be tightly combined with susceptible cells and effectively prevent Mycobacterium tuberculosis H37Rv from invading cells The natural structure and hydrophilicity of these three polypeptides are good, so they are suitable for artificial synthesis. Using chitosan-deoxycholic acid conjugate as a carrier can stimulate the body's effective humoral and cellular immune responses.

The invention relates to a mycobacterium tuberculosis H37Rv coding gene, which can be used as a standard gene for molecular identification of mycobacterium tuberculosis complex, and is used for molecular identification and clinical detection of mycobacterium tuberculosis complex.

The present invention relates to a Mycobacterium tuberculosis H37Rv coding gene and its application, in particular to a new missing annotation coding gene Rv3128 (+|3493573‑3493707|), which can be used as a standard gene for molecular identification of Mycobacterium tuberculosis complex, For molecular identification and clinical detection of Mycobacterium tuberculosis complex.

The invention relates to a mycobacterium tuberculosis H37Rv coding gene, which can be used as a standard gene for molecular identification of mycobacterium tuberculosis complex, and is used for molecular identification and clinical detection of mycobacterium tuberculosis complex.

The invention relates to a mycobacterium tuberculosis (MTB) H37Rv coding gene and application thereof, in particular to a new annotation omitting coding gene Rv0229A (-|274710-274904|). The new annotation omitting coding gene can be used as a standard gene for molecular identification of a mycobacterium tuberculosis complex (MTBC), and is used for molecular identification and clinical detection ofthe MTBC.

The invention relates to a mycobacterium tuberculosis H37Rv coding gene, which can be used as a standard gene for molecular identification of mycobacterium tuberculosis complex, and is used for molecular identification and clinical detection of mycobacterium tuberculosis complex.

The invention relates to a mycobacterium tuberculosis H37Rv coding gene, which can be used as a standard gene for the molecular identification of the mycobacterium tuberculosis complex, and is used for the molecular identification and clinical detection of the mycobacterium tuberculosis complex.

The present invention relates to a Mycobacterium tuberculosis H37Rv coding gene and its application, in particular to a new missing annotation coding gene Rv1796c (‑|2034439‑2034570|), which can be used as a standard gene for molecular identification of Mycobacterium tuberculosis complex, For molecular identification and clinical detection of Mycobacterium tuberculosis complex.

Relating to a vaccine preparation method, the invention provides a preparation method of a Mycobacterium tuberculosis Ag85A oral DNA vaccine. The method comprises: designing a pair of PCR primers according to a gene sequence of Mycobacterium tuberculosis Ag85A, taking the DNA of a human Mycobacterium tuberculosis H37Rv standard virulent strain as a template, conducting PCR amplification to obtain an Ag85A gene, subjecting a recycled PCR product to enzyme digestion by restriction endonuclease Xhol and BamHI, then connecting the product with a eukaryotic vector pCDNA3.1+ through a T4DNA ligase action, proving an obtained positive clone as the Ag85A gene by a DNA sequencing identification, cloning the Ag85A gene to the downstream of a CMV promoter in the vector pCDNA3.1+, constructing a recombinant plasmid pCDNA3.1+ / Ag85A, which is then transformed into Escherichia coli and amplified, thus obtaining the Mycobacterium tuberculosis Ag85A oral DNA vaccine. The method lays a foundation for clinical application research of oral DNA vaccines.